Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Sotyktu. Always confirm against the full prescribing information.
100 interactions
Acetaminophen
The serum concentration of Acetaminophen can be increased when it is combined with Deucravacitinib.
Level 2 evidence
Anthrax immune globulin human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Deucravacitinib.
Level 2 evidence
AstraZeneca COVID-19 Vaccine
The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Deucravacitinib.
The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Deucravacitinib.
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Deucravacitinib.
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Deucravacitinib.
Level 2 evidence
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Deucravacitinib.
Level 1 evidence
Ebola Zaire vaccine (live, attenuated)
The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Deucravacitinib.
Level 2 evidence
Elasomeran
The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Deucravacitinib.
Level 2 evidence
Etrasimod
The risk or severity of immunosuppression can be increased when Deucravacitinib is combined with Etrasimod.
Level 1 evidence
Fingolimod
Deucravacitinib may increase the immunosuppressive activities of Fingolimod.
Level 1 evidence
Allogeneic processed thymus tissue
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Deucravacitinib.
Level 2 evidence
Enter your NPI to unlock 86 major interactions for Sotyktu
Sotyktu (Deucravacitinib) has 277 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Sotyktu (Deucravacitinib) has 218 major, 53 moderate, and 6 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Sotyktu. Always confirm against the full prescribing information.